Vanda rises on tasimelteon NDA anticipation
This article was originally published in Scrip
Executive Summary
Shares of Vanda Pharmaceuticals got a 2.5% bump, or a gain of 10 cents, on 25 March after the company said the FDA confirmed that the efficacy and safety data proposed by the company to be submitted in the tasimelteon new drug application (NDA) is adequate to support a filing for the experimental medicine as a treatment for non-24-hour disorder, a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.